Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera & Marta García Dorado. (2018) An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). International Journal of Psychiatry in Clinical Practice 22:3, pages 191-199.
Read now
Read now
HuaFang Li, Ibrahim Turkoz & Fan Zhang. (2016) Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study. Neuropsychiatric Disease and Treatment 12, pages 15-24.
Read now
Read now
Richard Newton, Harry Hustig, Raju Lakshmana, Joseph Lee, Balaji Motamarri, Peter Norrie, Robert Parker & Andreas Schreiner. (2012) Practical guidelines on the use of paliperidone palmitate in schizophrenia. Current Medical Research and Opinion 28:4, pages 559-567.
Read now
Read now
Articles from other publishers (13)
Sandeep Grover, Swapnajeet Sahoo & Aseem Mehra. (2019) Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology 39:6, pages 611-619.
Crossref
Crossref
Pierre-Michel Llorca, Julio Bobes, W. Wolfgang Fleischhacker, Stephan Heres, Nicholas Moore, Nawal Bent-Ennakhil, Christophe Sapin, Jean-Yves Loze, Anna-Greta Nylander & Maxine X. Patel. (2020) Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. European Psychiatry 52, pages 85-94.
Crossref
Crossref
Miguel Bernardo, Fernando Cañas, Berta Herrera & Marta García Dorado. (2017) Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community. Revista de Psiquiatría y Salud Mental (English Edition) 10:3, pages 149-159.
Crossref
Crossref
Miguel Bernardo, Fernando Cañas, Berta Herrera & Marta García Dorado. (2017) La adherencia predice la remisión sintomática y psicosocial en esquizofrenia: estudio naturalístico de la integración de los pacientes en la comunidad. Revista de Psiquiatría y Salud Mental 10:3, pages 149-159.
Crossref
Crossref
Taro Kishi, Kazuto Oya & Nakao Iwata. (2016) Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Research 246, pages 750-755.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Nam Young Lee, Se Hyun Kim, Seong Jin Cho, Young-Cho Chung, In Kwa Jung, Chang Yoon Kim, Duk Ho Kim, Dong Geun Lee, Yo Han Lee, Weon Jeong Lim, Young Suk Na, Sang Eun Shin, Jong-Min Woo, Jin Sang Yoon, Bo-Hyun Yoon, Yong Min Ahn & Yong Sik Kim. (2014) A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. International Clinical Psychopharmacology 29:5, pages 279-287.
Crossref
Crossref
Anna-Sophia Rauch & W. Wolfgang Fleischhacker. (2013) Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective. CNS Drugs 27:8, pages 637-652.
Crossref
Crossref
Hyun-Ghang Jeong & Moon-Soo Lee. (2013) Long-acting Injectable Antipsychotics in First-episode Schizophrenia. Clinical Psychopharmacology and Neuroscience 11:1, pages 1-6.
Crossref
Crossref
Matthias Kirschner, Anastasia Theodoridou, Paolo Fusar-Poli, Stefan Kaiser & Matthias Jäger. (2012) Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Therapeutic Advances in Psychopharmacology 3:2, pages 89-99.
Crossref
Crossref
Lamiae Grimaldi-Bensouda, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beaufils, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut & Lucien Abenhaim. (2012) Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia Research 134:2-3, pages 187-194.
Crossref
Crossref
José M Olivares, Beatriz Pinal & Carmen Cinos. (2011) Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry 1:3, pages 275-289.
Crossref
Crossref
Javier Quintero, Eduardo Barbudo, Juan D. Molina, Carlos Mur, Antonio Ceverino, Eloy Garcia-Resa & Javier Correas Lauffer. (2011) The Effectiveness of the Combination Therapy of Amisulpride and Quetiapine for Managing Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 31:2, pages 240-242.
Crossref
Crossref